Metrics manifesting the strongest concurrent validity with providers identified from these records related to those who co-prescribed benzodiazepines (e.g., valium) and high levels of opioid analgesics (e.g., oxycodone), as well as those who wrote temporally overlapping prescriptions. The report concludes with a discussion of a variety of uses to which these metrics may be put, as well as problems and opportunities related to their use. (Publisher abstract modified)
Downloads
Similar Publications
- Comparison of Universal Mental Health Screening to Students Already Receiving Intervention in a Multitiered System of Support
- NPS Discovery Q2 2025 TREND REPORTS: NPS Benzodiazepines, NPS Opioids, NPS Stimulants & Hallucinogens, and Synthetic Cannabinoids in the U.S.
- Proteomic genotyping: Using mass spectrometry to infer SNP genotypes in a forensic context